Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 2
2002 1
2004 1
2007 2
2008 2
2009 4
2010 4
2011 5
2012 4
2013 10
2014 14
2015 15
2016 11
2017 10
2018 20
2019 9
2020 15
2021 12
2022 9
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Results by year

Filters applied: . Clear all
Page 1
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: vervloet mg. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
Magnesium Administration in Chronic Kidney Disease.
Vermeulen EA, Vervloet MG. Vermeulen EA, et al. Among authors: vervloet mg. Nutrients. 2023 Jan 20;15(3):547. doi: 10.3390/nu15030547. Nutrients. 2023. PMID: 36771254 Free PMC article. Review.
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study.
Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, Taveira-Gomes T, Botana M, Birkeland KI, Thuresson M, Jäger L, Sood MM, VanPottelbergh G, Tangri N; CaReMe CKD Investigators. Sundström J, et al. Among authors: vervloet mg. Lancet Reg Health Eur. 2022 Jun 30;20:100438. doi: 10.1016/j.lanepe.2022.100438. eCollection 2022 Sep. Lancet Reg Health Eur. 2022. PMID: 36090671 Free PMC article.
Oxidation of parathyroid hormone.
Ursem SR, Vervloet MG, de Jongh RT, Heijboer AC. Ursem SR, et al. Among authors: vervloet mg. Clin Chim Acta. 2020 Jul;506:84-91. doi: 10.1016/j.cca.2020.03.020. Epub 2020 Mar 13. Clin Chim Acta. 2020. PMID: 32178977 Review.
Circulating markers of bone turnover.
Vervloet MG, Brandenburg VM; CKD-MBD working group of ERA-EDTA. Vervloet MG, et al. J Nephrol. 2017 Oct;30(5):663-670. doi: 10.1007/s40620-017-0408-8. Epub 2017 May 13. J Nephrol. 2017. PMID: 28502032 Free PMC article. Review.
Vitamin D in CKD: An Unfinished Story.
Hsu S, Vervloet MG, de Boer IH. Hsu S, et al. Among authors: vervloet mg. Am J Kidney Dis. 2023 Nov;82(5):512-514. doi: 10.1053/j.ajkd.2023.07.005. Epub 2023 Sep 16. Am J Kidney Dis. 2023. PMID: 37715768 No abstract available.
The role of phosphate in kidney disease.
Vervloet MG, Sezer S, Massy ZA, Johansson L, Cozzolino M, Fouque D; ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group. Vervloet MG, et al. Nat Rev Nephrol. 2017 Jan;13(1):27-38. doi: 10.1038/nrneph.2016.164. Epub 2016 Nov 21. Nat Rev Nephrol. 2017. PMID: 27867189 Review.
134 results